May 15, 2024Open Access

Clinical Management of Patients With Relapsed/Refractory Multiple Myeloma Treated With Talquetamab

Key Points

Overall response rates exceed 71% for talquetamab in relapsed/refractory multiple myeloma patients, showing promising efficacy.
The MonumenTAL-1 trial enrolled patients heavily pre-treated with triple-class therapy for multiple myeloma.
Assessment of adverse events revealed unique patterns linked to the GPRC5D target and T-cell redirection strategies employed with talquetamab administration. Management strategies are provided for obstacles associated with adverse events, suggesting how to enhance treatment tolerability.

Abstract

Talquetamab is a bispecific antibody targeting the multiple myeloma-associated antigen G protein-coupled receptor family C group 5 member D (GPRC5D). In the phase 1/2 MonumenTAL-1 trial (NCT03399799/NCT04634552), overall responses rates were > 71% in patients with triple-class exposed relapsed/refractory multiple myeloma (RRMM). Due to the distribution of the target antigen, a unique pattern of GPRC5D-associated adverse events (AEs) was observed, together with T-cell redirection-associated AEs. Management strategies for talquetamab-associated AEs are described.

Read Full Paperexternally

AI에게 질문

Bookmark

View Full Paper